The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
The Third Intergroup Rhabdomyosarcoma Study.
Abstract
PURPOSE: The ultimate goal of the Third Intergroup Rhabdomyosarcoma Study (IRS-III, 1984 to 1991) was to improve treatment outcome in children with rhabdomyosarcoma through clinical trials comparing risk-based protocols of surgery and multiagent chemotherapy, with or without irradiation. PATIENTS AND METHODS: One thousand sixty-two previously untreated, eligible patients who were entered onto the study after surgery were randomized or assigned to treatment by clinical group (I through IV), histology (unfavorable or favorable), and site of the primary tumor. Initial responses, progression-free survival (PFS), and survival (S) were the end points used in comparisons between randomized groups and between patients treated in IRS-III and IRS-II (1978 to 1984). RESULTS: The overall outcome of therapy in IRS-III was significantly better than in IRS-II (5-year PFS, 65% +/- 2% v 55% +/- 2%; P < .001 by stratified testing). Patients with group I favorable-histology tumors fared as well on a 1-year regimen of vincristine and dactinomycin (VA), as did a comparable group treated with VA plus cyclophosphamide (C) (5-year PFS, 83% +/- 3% v 76% +/- 4%; P = .18). Results for patients with group II favorable-histology tumors, excluding orbit, head, and paratesticular sites, were inconclusive regarding the benefit from addition of doxorubicin (ADR) to VA. Patients with group III tumors, excluding those in special pelvic, orbit, and other selected nonparameningeal head sites, fared much better on the more intensive regimens of IRS-III than on pulsed VAC or VAC-VADRC in IRS-II (5-year PFS estimates, 62% +/- 3% v 52% +/- 3%; P < .01); however, there were no significant differences in outcome among the groups treated in IRS-III. Patients with metastatic disease at diagnosis (clinical group IV) did not benefit significantly from the more complex therapies evaluated in IRS-III. CONCLUSION: Intensification of therapy for most patients in IRS-III, using a risk-based study design, significantly improved treatment outcome overall. The largest gain from this strategy was realized in patients with gross residual tumor after biopsy (clinical group III). It was also possible to decrease therapy for selected patient subsets without compromising survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
Self-citationCardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid Leukemia
Pui, C.-H., Behm, F. G., Raimondi, S. C., Dodge, R. K., George, S. L., Rivera, G. K., Mirro, J., Kalwinsky, D. K., Dahl, G. V., Murphy, S. B., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210302 · Cited by 441
Self-citationShapiro, D. N., Sublett, J. E., Li, B., Downing, J. R., & Naeve, C. W. (1993) · PubMed · Cited by 383
Crist, W. M., Garnsey, L., Beltangady, M. S., Gehan, E., Ruymann, F., Webber, B., Hays, D. M., Wharam, M., & Maurer, H. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.3.443 · Cited by 286
Self-citationApproaches to sample size estimation in the design of clinical trials—a review
Donner, A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030302 · Cited by 250
Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseases
TAN, C. T. C., Etcubanas, E., Wollner, N., Rosen, G., Gilladoga, A. C., Showel, J. L., Murphy, M. L., & Krakoff, I. H. (1973) · Cancer · doi:10.1002/1097-0142(197307)32:1<9::aid-cncr2820320102>3.0.co;2-6 · Cited by 235
Sample size requirements for evaluating a conservative therapy.
Makuch, R., & Simon, R. M. (1978) · PubMed · Cited by 228
Common Solid Tumors of Childhood
Crist, W. M., & Kun, L. E. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240706 · Cited by 208
Self-citationHeyn, R., Haeberlen, V, Newton, W. A., Ragab, A. H., Raney, R. B., Tefft, M., Wharam, M., Ensign, L. G., & Maurer, H. M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.262 · Cited by 192
Self-citationMethodologic guidelines for reports of clinical trials.
Simon, R. M., & Wittes, R. E. (1985) · PubMed · Cited by 133
Horowitz, M. E., Etcubanas, E., Christensen, M. L., et al. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.308 · Cited by 111
Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis
Rodary, C., Rey, A., Olive, D., Flamant, F., Quintana, E., Brunat-Mentigny, M., Otten, J., & Voûte, P. A. (1988) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950160202 · Cited by 64
Gasparini, M., Lombardi, F., Gianni, M., Massimino, M., Gandola, L., & Fossati‐Bellani, F. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1854 · Cited by 25
(1993) · doi:10.1002/1097-0142(19930301)71:5<1904::aid-cncr2820710530>3.0.co;2-x
(1988) · doi:10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l
Cited by
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Crist, W. M., Anderson, J. R., Meza, J. L., Fryer, C., Raney, R. B., Ruymann, F. B., Breneman, J., Qualman, S. J., Wiener, E., Wharam, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3091 · Cited by 1,087
Self-citationSkapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, J., Barr, F. G., & Hawkins, D. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0051-2 · Cited by 875
Sorensen, P. H. B., Lynch, J. C., Qualman, S. J., Tirabosco, R., Lim, J. F., Maurer, H. M., Bridge, J. A., Crist, W. M., Triche, T. J., & Barr, F. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.137 · Cited by 742
Self-citationCommon Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657
Self-citationOberlin, O., Rey, A., Lyden, E., Bisogno, G., Stevens, M. C. G., Meyer, W. H., Carli, M., & Anderson, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7207 · Cited by 484
Metadata
- Authors
- Crist, W., Gehan, E. A., Ragab, A. H., Dickman, P. S., Donaldson, S. S., Fryer, C., Hammond, D., Hays, D. M., Herrmann, J., & Heyn, R.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-03
- Volume
- 13
- Issue
- 3
- Pages
- 610-630
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1693048258
- Cited by
- 999
- References
- 19
- FWCI
- 24.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.